Full-Time

Field Medical Director Internal Medicine/Emergency Medicine

Cardiology

Evolent

Evolent

1,001-5,000 employees

Delivers value-based care through analytics

Compensation Overview

$96 - $100/hr

Company Does Not Provide H1B Sponsorship

Remote in USA

Remote

Remote within the United States; final interviews may require onsite attendance.

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Quality Assurance (QA)

Get referred to Evolent

See people who can refer or advise you

Requirements
  • A Doctor of Osteopathic Medicine, Doctor of Medicine, or Bachelor of Medicine, Bachelor of Surgery degree from an accredited institution.
  • Current board certification in Emergency Medicine or Internal Medicine by an American Certifying Board.
  • A current, unrestricted medical license in one or more U.S. states.
  • A current unrestricted medical license in the home state.
  • Strong knowledge of diagnostic cardiology, including evaluation and management of cardiovascular conditions, and appropriate use of cardiac imaging modalities such as echocardiography, nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance imaging to support evidence-based medical necessity determinations.
  • High-speed internet over 10 Mbps at home and, for call center employees, the ability to plug directly into the home internet router.
Responsibilities
  • Serve as the specialty-match reviewer for diagnostic cardiology cases that do not initially meet applicable medical necessity guidelines, as well as other requests requiring review by a cardiology subject matter expert.
  • Review cases in which clinical determinations cannot be made by Initial Clinical Reviewers, ensuring appropriate use of evidence-based cardiology guidelines and regulatory standards.
  • Provide clear, evidence-based clinical rationale for standard and expedited appeals.
  • Conduct peer-to-peer discussions with requesting physicians or ordering providers, when available, within regulatory timeframes by phone.
  • Use medical and clinical review guidelines and parameters to ensure consistency in physician review processes and appropriate utilization, in alignment with SBU policies and procedures, Utilization Review Accreditation Commission standards, and National Committee for Quality Assurance standards.
  • Assist and act as a clinical resource to Field Medical Directors and Initial Clinical Reviewers by discussing cases, addressing complex review scenarios, and supporting problem resolution.
  • Ensure communications with medical office staff and physician providers are documented accurately and in a timely manner.
  • Participate in ongoing training initiatives, including inter-rater reliability programs, to promote quality, consistency, and compliance.
  • Assist the Senior Medical Director, as requested, with research activities and questions related to utilization management processes, guideline interpretation, and system or operational support.
  • Review appeal cases and/or attend hearings on request to support utilization management determinations.
  • Function as Medical Director for select health plans or regions on request, assuming overall accountability for utilization management activities in collaboration with the Senior Medical Director.
Desired Qualifications
  • Five (5) years of post-residency clinical experience.
  • Strong verbal and written communication skills, including the ability to effectively engage in peer-to-peer discussions with treating providers.
  • Proficient computer skills and experience working with clinical review and documentation systems.
  • Active clinical practice experience within the past 18 months.
  • Familiarity with utilization management principles and procedures within managed care organizations, including experience with cost-benefit analysis, quality assurance, and continuous quality improvement processes.

Evolent Health helps healthcare organizations transition to value-based care by pairing technology, analytics, and clinical expertise to improve patient outcomes while lowering costs. It partners with health systems, physician groups, and health plans to deliver data-driven care coordination, population health management, and risk-adjustment services. The company’s offerings include software platforms, analytics, and clinical support that enable more efficient care delivery, shared savings programs, and performance-based incentives. Compared with competitors, Evolent emphasizes end-to-end collaboration with clients and a diversified client base, combining technology with hands-on clinical and operational expertise to drive measurable outcomes. Its goal is to help clients succeed in value-based models by delivering better patient care at lower total costs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Arlington, Virginia

Founded

2011

Get referred to Evolent

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $652.5 million, and guidance rose to $2.65 billion.
  • Oncology agreement covers 1.5 million lives and targets $300 million annualized revenue.
  • AI automation and Auth Intelligence lifted efficiency, supporting 2027 EBITDA above $150 million.

What critics are saying

  • Q2 2026 net debt hit $808.3 million, forcing 2029 refinancing before growth stalls.
  • Medical expense pressure and 6.4x leverage threaten margins if claims deteriorate in 2026.
  • Any Highmark or Aetna contract failure would crush credibility and trigger covenant stress.

What makes Evolent unique

  • Evolent combines oncology, authorization automation, and value-based care under one payer-facing platform.
  • Archie Mayani joined March 2026, strengthening AI product execution across clinical workflows.
  • Highmark and Aetna launches prove Evolent wins large-plan integrations competitors still struggle to replicate.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Hybrid Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 15th, 2026
Evolent Health beats Q2 revenue estimates by 9.4%, raises full-year guidance to $2.65B

Evolent Health reported strong second-quarter results, beating revenue expectations with $652.5 million versus the anticipated $596.7 million, representing 46.9% year-on-year growth. The company also surpassed adjusted earnings per share and EBITDA forecasts. CEO Seth Blackley attributed the performance to successful contract launches with Highmark and robust customer renewals. Clinical engagement metrics for new partnerships with Aetna and Highmark exceeded targets, demonstrating strong execution in value-based care solutions. The company raised its full-year revenue guidance to $2.65 billion at the midpoint, up 6% from the previous $2.5 billion forecast. EBITDA guidance remained at $127.5 million. During the earnings call, management addressed analyst questions about reserving processes, margin trends in new contracts, and pipeline development. Blackley noted the business pipeline has refilled with several large national plans under consideration, particularly in oncology services.

Yahoo Finance
Aug 10th, 2026
Evolent Health beats revenue estimates with $652.5M, raises full-year guidance to $2.65B on AI automation gains

Evolent Health reported Q2 2026 revenue of $652.5 million, up 46.9% year-on-year and beating analyst estimates by 9.4%. The healthcare solutions company's full-year revenue guidance of $2.65 billion came in 5.9% above consensus. CEO Seth Blackley highlighted the successful launch of the Highmark contract and strong clinical engagement metrics for new partnerships with Aetna and Highmark. The company's Auth Intelligence automation platform contributed to operational efficiency gains. Management pointed to expansion of its oncology Performance Suite and accelerated deployment of its AI-enabled authorisation platform as key growth drivers. Blackley stated Q2 represented "a tipping point in our AI journey" as efforts moved beyond pilot phases to meaningful scale. The company expects cost-saving initiatives and improved operating leverage to offset headwinds from Medicaid and exchange membership pressures.

Yahoo Finance
Aug 6th, 2026
Evolent Health revenue surges 31% to $653M, raises 2026 guidance to $2.7B

Evolent Health reported strong second-quarter 2026 results, with total revenue reaching $653 million, up 31% from the previous quarter. Adjusted EBITDA rose 27% quarter-over-quarter to $28 million. The healthcare technology company raised its full-year 2026 revenue guidance to between $2.6 billion and $2.7 billion. It tightened adjusted EBITDA guidance to a range of $120 million to $135 million. Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualised revenue. The company also secured a contract extension with a regional Blue Cross plan. The firm ended Q2 with $115.7 million in unrestricted cash and $808.3 million of net debt. For 2027, Evolent expects revenue growth exceeding 25%.

Yahoo Finance
Jun 12th, 2026
Evolent Health posts weakest Q1 revenue growth among healthcare tech providers despite $496M earnings

Evolent Health reported Q1 revenues of $496.2 million, up 2.6% year on year, but falling short of analysts' expectations by 6.9%. The healthcare technology company, which provides specialty care management services for patients with complex conditions, delivered mixed results with an earnings per share beat but a significant revenue miss. The healthcare technology for providers sector showed overall strength in Q1, with the four tracked stocks beating revenue consensus estimates by 1.1% on average. Share prices have risen 7.7% on average since earnings results. Despite having the weakest performance against analyst estimates and slowest revenue growth in the group, Evolent Health raised its full-year guidance the most. The stock has climbed 21.5% since reporting and currently trades at $4.65.